Special survey of Olmetec Tablets (olmesartan medoxomil) for long-term use-Safety and efficacy in patients less than and over 65 years and especially those over 75 years of age during a 2-year administration-
Law MR, Wald NJ, Morris JK, et al.: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ, 326: 1427-1431, 2003.
Fliser D, Buchholz K, Haller H: Antiinflammatory Effects of Angiotensin II Subtype 1 Receptor Blockade in Hypertensive Patients With Microinflammation. Circulation, 110: 1103-1107, 2004.
Stumpe KO, Agabiti-Rosei E, Zielinski T, et al.: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study. Ther Adv Cardiovasc Dis, 1: 97-106, 2007.
Smith RD, Yokoyama H, Averill DB, et al.: Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. Am J Hypertens.2: 165-172, 2008.